Next Article in Journal
Editorial for “Advances in Oral Diseases Diagnosis and Management: 2nd Edition”
Previous Article in Journal
Functional Outcomes and Activity Levels in Patients After Internal Hemipelvectomy for Primary Sarcoma Involving the Bony Pelvis
Previous Article in Special Issue
The Impact of Prior COVID-19 on Long-Term Mortality and Echocardiographic Predictors in Chronic Kidney Disease Patients
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Diagnostics
Volume 15
Issue 12
10.3390/diagnostics15121453
diagnostics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Pituitary Apoplexy in a Child with Short Stature and Possible Recent SARS-CoV-2 Infection

by
Carmen Gabriela Barbu
1,2,
Luminita Nicoleta Cima
1,2,
Marian Andrei
2,*,
Simona Vasilache
3,
Mihaela Țarnă
2,
Ileana Olguta Rizea
4,
Carmen Sorina Martin
1,2,
Anca Elena Sîrbu
1,2 and
Simona Fica
1,2
1
Department of Endocrinology, Diabetes Mellitus, Nutrition and Metabolic Disorders, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania
2
Department of Endocrinology, Diabetes Mellitus, Nutrition and Metabolic Disorders, Elias Emergency University Hospital, 011461 Bucharest, Romania
3
Endocrinology Ambulatory Care Center, Pediatric Hospital, 100336 Ploiesti, Romania
4
Department of Radiology and Medical Imaging, Elias Emergency University Hospital, 011461 Bucharest, Romania
*
Author to whom correspondence should be addressed.
Diagnostics 2025, 15(12), 1453; https://doi.org/10.3390/diagnostics15121453
Submission received: 26 April 2025 / Revised: 3 June 2025 / Accepted: 5 June 2025 / Published: 7 June 2025
(This article belongs to the Special Issue Symptoms, Diagnosis, Prognosis and Management of Long COVID or Post-COVID Conditions, 2nd Edition)
Browse Figures
Review Reports Versions Notes

Abstract

Background and Clinical Significance: Pituitary apoplexy is an extremely rare condition in children and adolescents with a rapid onset due to acute hemorrhage, infarction, or both in the pituitary gland. Most frequently, pituitary apoplexy is an asymptomatic or subclinical entity. Few cases of pituitary apoplexy with concurrent SARS-CoV-2 infection or COVID-19 vaccination have been reported. Case Presentation: We present the case of a 13-year-8-month-old boy who presented in our pediatric endocrinology department for the evaluation of short stature. He was previously diagnosed with secondary hypothyroidism and was treated with levothyroxine. At admission, clinical examination revealed a height of 141 cm (−2.68 SD/−2.4 SD corrected for mid-parental height), normal weight (60th centile), Tanner-stage G2P1, and delayed bone age. Basal IGF1 was normal, but the tests performed to assess the GH reserve confirmed the GH deficiency (peak GH value 3.11 ng/mL after clonidine/0.95 ng/mL after insulin). The brain MRI revealed a subacute pituitary hemorrhage. Thrombophilia and coagulopathies were excluded by further testing. Anti-SARS-CoV-2 (anti-S-protein IgG) antibodies (>200 BAU/mL) were compatible with COVID-19 infection, indicating a possible association between these two entities. At 3-month follow-up, physical examination showed a 3 cm height gain and advancing pubertal development (G4P2). Newer MRI found changes consistent with resolving hemorrhage. The patient was provided immediately with recombinant human GH and aromatase inhibitor therapy to maximize GH treatment response. During follow-up, the rGH dose was adjusted based on IGF1 values, and after 3 years and 10 months, rGH treatment was stopped, reaching a height of 172.3 cm (−0.51 SD) and surpassing the initial prediction of 164.5 cm. Conclusions: Pituitary apoplexy, an even rarer complication in the pediatric population, may be associated with SARS-CoV-2 infection. Further studies are necessary to better understand the intertwining of those conditions.

1. Introduction

Pituitary apoplexy is a clinical entity characterized by the sudden onset of hemorrhage, infarction, or hemorrhagic infarction, most commonly of a pituitary adenoma [1]. Depending on the definition used by the authors, the reported incidence for symptomatic pituitary apoplexy varies from 0.6% to 9% and from 14% to 22% for subclinical pituitary apoplexy [2,3].
Various studies and case reports identified numerous risk factors for this condition, such as the following: systemic hypertension; major surgery; coagulopathies; dynamic pituitary function tests with TRH, GnRH, CRH, or insulin; estrogen therapy; pregnancy and post-partum states; various medications; radiation therapy; head trauma; pituitary surgery; and gamma knife therapy [4,5,6,7,8,9,10,11,12,13].
In children and adolescents, due to the overall rarity of pituitary adenoma in this age group, accurate information regarding pituitary apoplexy is lacking, and the reported incidence varies from 1.8 to 7.5% of all surgically treated pituitary adenomas. Given the unclear definition of pituitary apoplexy, there is no clear consensus about its characteristics in this age group [3,14].
Recently, during the COVID-19 outbreak, pituitary apoplexy cases in association with this infection have been reported, mostly in the adult population [15]. Almost every case of this kind has an underlying etiology, such as a pituitary adenoma. However, there are case reports with no pre-existing risk factors [16,17].

2. Case Presentation

We report the case of a 13-year-8 month-old boy who presented in our endocrinology department due to short stature in November 2021. He was previously evaluated by his territorial endocrinologist and had a repeated slightly lowered FT4 with normal TSH levels and multiple low IGF1 determinations. This prompted his physician to prescribe 25 μg of levothyroxine a day and refer him to our clinic for further investigations. The child was delivered by C-section at 37 weeks, had a birth weight of 3.4 kg, a birth length of 50 cm, and a normal psychomotor development. At admission, his height was 141 cm (−2.68 SD or −2.4 SD if corrected for mid-parental height SDS), weight was 39 kg (60th centile), and head circumference was 59 cm (98th centile), and he had an upper segment to lower segment ratio of 1.09. His pubertal development was G2P1 with a bone age of 12 years. Biological evaluations showed no abnormality in routine blood tests and liver function, normal adrenal and gonadal function, and a prolactin level of 9 ng/mL. Thyroid function was normal with an FT4 level of 1.14 ng/dL and a TSH of 1.69 μU/mL on 25 μg of levothyroxine. Basal IGF1 was detected to be within the normal range, with a value of 116.1 ng/mL (normal values for ages 64–508), and after a provocative test, the peak GH value was 3.11 ng/mL after the oral administration of clonidine and 0.95 ng/mL after an insulin administration of 0.1 UI/kg iv. Adrenal response during ITT was partially present, with a peak cortisol level of 18.1 μg/dL. Before prescribing treatment with recombinant human GH, we performed a brain MRI, which revealed subacute pituitary hemorrhage, as seen in Figure 1. The posterior pituitary bright spot was present, and the pituitary stalk was a normal size.
Ophthalmological testing showed no visual deficits or oculomotor alterations, and having no clinical symptoms of pituitary apoplexy, transsphenoidal surgery was not necessary. This prompted us to discharge the patient with only 25 μg levothyroxine/day and 3-month follow-up MRI. Screening tests for coagulopathies were recommended, and the results were negative. Focusing on the etiology of the pituitary apoplexy, we initially considered Rathke cleft cysts or sellar/suprasellar tumors. Subsequent MRI examination found changes consistent with resolving hemorrhage, weakening the hypothesis for a Rathke cleft cyst. However, physical examination revealed an almost 3 cm height gain with an advanced pubertal development (G4P2). According to this new data and the Bone Expert final height prediction of 164.5 cm, the patient was provided immediately with recombinant human GH 0.03 mg/kg/day, and to maximize GH treatment response, we utilized 2.5 mg of letrozole, based on published case reports. For normal thyroid function, the levothyroxine dose was adjusted to 50 μg/day, and during follow-up, it was adjusted to 100 μg/day. Also, we measured anti-SARS-CoV-2 (anti-S-protein IgG) antibodies (>200 BAU/mL) after the mother mentioned that the boy had a respiratory infection before being first admitted to our pediatric endocrinology department for testing the GH reserve that might have been responsible for the subacute pituitary hemorrhage. During the 3-year follow-up, he was reexamined every 6 months, adjusting the rGH dose based on IGF1 values and body weight, as summarized in Table 1.
Note the IGF1 fluctuation during the follow-up period. It is well known that in healthy children, during pubertal development, IGF1 rises significantly, reaching levels even in the acromegalic range [18]. This is explained by the fluctuating levels of gonadotropins (FSH and LH) and testosterone, transient insulin resistance, and the concurrent rise in IGF-binding protein 3 (IGFBP-3) and the acid-labile subunit (ALS) [19]. Even though we have a GH-deficient patient, these physiological hormonal variations should explain the IGF1 fluctuation. We asked the laboratory department to retest the November 2023 blood sample, and the result was similar, excluding a testing error.
After approximately 2 years of treatment, letrozole was stopped, and in November 2024, rGH treatment was also stopped, given the bone age of 16 years. The patient’s height during the 3 years and 10 months of rGH treatment is shown in Figure 2, reaching 172.3 cm (−0.51 SD) at the last evaluation and surpassing his initial height prediction of 164.5 cm.
As seen in Figure 3, the latest MRI investigation performed in March 2025, as well as other MRI investigations during follow-up, revealed the presence of hemoglobin breakdown products located within the anterior lobe of the pituitary gland, strengthening the hypothesis of a pituitary apoplexy without an adenoma.

3. Discussion

Pituitary adenomas are generally the main cause of pituitary apoplexy. Pituitary tumors may produce ophthalmologic symptoms such as visual field defects most frequently, a sudden loss of vision, ophthalmoplegia, or papilledema in rare cases [5,21]. In the case of an acute pituitary hemorrhage or apoplexy, the most common and prominent symptom is headaches, often accompanied by nausea and vomiting. They manifest due to dural traction or the extravasation of blood and necrotic material into the subarachnoid space [3,22,23]. Our patient did not complain of any visual impairments or headaches. However, he presented with signs of pituitary insufficiency, like delayed growth and secondary hypothyroidism. The most life-threatening and frequently encountered hormonal complication is corticotropic deficiency, evolving with severe hypotension and hyponatremia [3,22,24]. In our case, this complication was absent.
The hypothalamic–pituitary gonadal axis functioned properly in our patient, leading to the normal progression of puberty with advancing bone age. Therefore, the most pressing matter, from an endocrinologist’s point of view, was the GH-deficient short stature with an advanced pubertal development, therefore predicting a rapid epiphyseal fusion and a shorter adult height. Having this in mind, we started the rGH treatment, and to delay growth plate fusion, the options were, according to literature data, to associate either a GnRH analogue or an aromatase inhibitor [25].
Suppressing normally timed puberty with a GnRH analogue presents a series of disadvantages, like creating a hypogonadal state at a critical time during development with diminishing whole-body protein synthesis and increasing adiposity. Furthermore, the child will not only be short but also sexually immature compared to his friends, leading to psychological implications. On the other hand, aromatase inhibitors block estrogen and increase testosterone production, leading to a slower growth plate fusion rate and increasing growth and lean body mass in males [25]. Having this in mind, together with the results of several studies and case reports, we decided to associate aromatase inhibitor therapy to maximize rGH treatment response by blocking estrogen production and delaying epiphyseal fusion [26,27,28]. As a result, after almost 3 years of rGH and 2 years of aromatase inhibitor treatment, our patient’s height improved, surpassing the initial predicted height by almost 10 cm and reaching a value close to the 50th percentile.
According to data we found in the literature, in the majority of cases, pituitary apoplexy happens in an underlying pituitary tumor [29]. In our case, the first MRI we have is after the apoplexy developed, and no pituitary adenoma was visible at that point in time; therefore, initially, we could not be certain if our patient had a preexisting adenoma. During follow-up, MRI examination was repeated every 6 months, with the last one in March 2025, with all of them describing no pituitary tumor, confirming the absence of a pituitary adenoma.
Another situation related to pituitary apoplexy in pediatric age is acute hemorrhage of a Rathke cleft cyst (RCC) [30]. Even though RCC hemorrhage can mimic pituitary apoplexy and baseline MRI cannot differentiate between the two entities, a subsequent MRI examination after 3 or 4 months should reveal a stable or growing lesion in the case of RCC hemorrhage, whereas in the case of a pituitary adenoma, it reveals tumor shrinkage [31]. In our case, the first MRI reexamination, carried out after 3 months, found changes consistent with resolving hemorrhage, standing against the diagnosis of RCC hemorrhage. Furthermore, no MRI examination during follow-up revealed a sellar/suprasellar tumor. Pituitary biopsy would have been the technique suited to settle the diagnosis dilemma; however, given the patient’s young age, the absence of any clinical symptoms, and surgical indications, pituitary biopsy was not carried out [32].
Lymphocytic hypophysitis, another condition that can mimic pituitary apoplexy, was excluded based on MRI examination. According to Kurokava et al., the most frequent findings of lymphocytic hypophysitis are loss of the posterior pituitary T1-weighted bright spot and enlarged pituitary stalk. Our patient had none of these findings, standing against this diagnosis [33].
Many other risk factors are described in the literature [29,34]. Some studies indicate clotting disorders as a precipitating factor. Anticoagulated states, whether from taking anticoagulant drugs, thrombolytic agents, or thrombocytopenia and even von Willebrand disease or clotting disorders due to liver disease, can lead to pituitary apoplexy, as emphasized by numerous reports [4,7,35]. Our workup excluded coagulopathies, and we obtained negative thrombophilia screening tests.
Some authors have demonstrated that stimulatory tests, like TRH, CRH, or GnRH testing, might be implicated in generating an apoplexy [8,9,11]. Even the insulin tolerance test is listed as a risk factor in some reports [36]. The exact mechanism is unknown. However, it was speculated that these tests may produce a vasoactive effect that initially leads to ischemia and infarction and later evolves to hemorrhage [7]. Other risk factors listed in the literature, like systemic hypertension, major surgery, estrogen therapy, pregnancy and post-partum states, various medications (dopamine receptor agonist, isosorbide, chlorpromazine, GnRH agonist, and clomiphene), radiation therapy, head trauma, pituitary surgery, and gamma knife therapy, can be easily excluded in this case [29]. Although this is very uncommon, having no previous imaging, we cannot rule out the possibility of a stimulating-test-induced pituitary apoplexy.
Recently, the novel coronavirus disease and SARS-CoV-2 vaccination have been recognized as risk factors for an apoplectic event [34,37,38,39,40]. Although most of the cases described are on a preexisting pituitary adenoma, there are reports of pituitary apoplexy attributed to COVID-19 in the absence of an underlying lesion [17,39,41,42].
While its most frequent clinical manifestation is respiratory distress, which varies from an asymptomatic carrier state to severe respiratory distress syndrome, there are many reports describing extrapulmonary involvement, with pituitary apoplexy being one of them [43,44,45].
The mechanism of such pathology might be hematological and immunological changes induced during infection [46]. The SARS-CoV-2 virus is now known to access neurons and glial cells using the ACE2 receptor and can cause a variety of clinical manifestations such as headache, ataxia, stroke, epilepsy, neuropathic pain, or myopathy. Those neurological symptoms have been attributed to immune-mediated mechanisms and are more likely in patients with severe cases of disease [47,48]. As it was demonstrated that the pituitary cells present ACE2 receptors, the invasion and direct cell death might be a plausible mechanism [49,50]. Aliberti et al. demonstrated, using immunohistochemical analysis in a case of PA, that SARS-CoV-2 proteins were present next to pituitary blood vessels, indicating that antigen cross-reactivity may play a role in inducing PA alongside the immune-mediated glandular damage secondary to antibody formation or cell-mediated damage [51,52]. Regarding the association between COVID-19 and coagulation abnormalities, data from the literature suggest that while the von Willebrand factor (vWF) is upregulated, ADAMTS13, a metalloprotease that cleaves high-molecular-weight vWF, is downregulated. This unbalanced ratio leads to the hypercoagulable state encountered in severe COVID-19, contributing to thrombosis in pituitary gland blood vessels and causing pituitary apoplexy [53,54].
Other hematological changes caused by COVID-19 are characterized by elevated fibrinogen and D-dimer levels, mild prolongation of PT/aPTT, and mild thrombocytopenia. Although COVID-19 is known more as a hypercoagulable state than a bleeding one, spontaneous hemorrhage may complicate a disease-induced thrombosis. Similarly to how pituitary apoplexy is associated with pregnancy, some authors propose an association between a hypercoagulable state and the apoplectic event; we can extrapolate to a link between the hypercoagulable state seen in COVID-19 patients and the occurrence of pituitary apoplexy [48,54,55,56].
Our patient exhibited a symptomatic respiratory infection 4 to 8 weeks before the first admission. Unfortunately, we have no confirmation of a SARS-CoV-2 infection with PCR or rapid antigen test, as it was a mild form of upper respiratory tract infection regarding respiratory symptoms that required no medical consultation. Taking into account this period of 1–2 months, we considered that the shift in antibody titers had happened, and no IgM measurements were carried out. However, we have a very high anti-SARS-CoV-2 (anti-S-protein IgG) antibody level. Numerous studies conducted during the pandemic have assessed the diagnostic accuracy of COVID-19 serological tests, and according to a 2023 meta-analysis, the reported median specificity was over 97% for many antibody tests, resulting in high specificity, particularly when IgG was tested [57]. Although we acknowledge the limitations of serological testing, particularly the potential for antibody cross-reactivity, in the absence of a positive PCR result and given the time elapsed since the suspected infection, serology was our only available method to support prior SARS-CoV-2 exposure. Overall, given the high antibody level and the strong specificity reported for IgG-based serology, there is a high probability that the upper respiratory tract infection in question was indeed COVID-19. Taking this into account, and in the absence of any other identifiable cause for pituitary apoplexy, this case strongly suggests a possible association between COVID-19 and the observed pituitary disease.
There is no consensus on whether early surgery should be performed. An appropriate treatment should be selected from several options, such as surgery (emergency, urgent, or elective) and supportive medical therapy, for each patient based on severity and timing [58,59,60].
Many studies have recommended that neurosurgical decompression should be the first-line treatment, especially in cases with serious neurologic deficits [61]. Others stated that there is no difference between the outcomes of surgical or conservatively treated patients and promoted a conservative management in patients with mild or no symptoms [62,63,64]. Our patient did not present any of these symptoms associated with pituitary apoplexy, and the diagnosis was settled only after imaging studies, so we opted for conservative management and hormonal replacement therapy.
Even though a number of cases of pituitary apoplexy have been reported as a manifestation of SARS-CoV-2 in the adult population, to our knowledge, this is the first pediatric case of pituitary apoplexy associated with SARS-CoV-2 [65]. Ohata et al. conducted a literature search in 2021 regarding cases of pituitary apoplexy in the pediatric population since 1980. They found 65 cases of pediatric pituitary apoplexy, all of them secondary to an adenoma, with most of them comprising macroadenoma [66]. Since 2021, other pediatric cases have been published, the majority of which had a pituitary adenoma, with one apoplexy secondary to RCC hemorrhage and one case with Langerhans cell histiocytosis who developed apoplexy after surgery [67,68,69,70]. Comparing our case with other pediatric cases of pituitary apoplexy, the main difference is the severity of the clinical symptoms. While most of the cases present with visual field defects and headache most frequently or a sudden loss of vision and ophthalmoplegia, often accompanied by nausea and vomiting and requiring decompression surgery, our patient had none of these, and he was brought in for a check-up after hormonal deficiencies manifested themselves. Regarding hormonal deficiencies, corticotropic deficiency was the most frequent hormonal complication in published apoplexy cases; however, in our patient, this complication was not present. What makes this case unique is the absence of a pituitary adenoma, with the description of changes consistent with resolving hemorrhage at every MRI investigation since diagnosis and the remaining link with a possible recent SARS-CoV-2 infection at that moment, suggesting an association between COVID-19 and the pituitary apoplexy.

4. Conclusions

Pituitary apoplexy is a rare entity, especially in the pediatric population. It may occur in patients with a preexisting pituitary adenoma or with several risk factors, including coagulopathies or dynamic pituitary function tests. Recently, pituitary apoplexy cases in association with the SARS-CoV-2 infection or COVID-19 vaccination have been reported, mostly in adults. We report the first known pediatric case of pituitary apoplexy in which a potential temporal association with COVID-19 was observed; however, causality could not be confirmed histologically. Even though we have no confirmation of pituitary damage through biopsy, which is possibly related to a SARS-CoV-2 infection confirmed by serology, this case contributes to the growing body of evidence suggesting a possible association between COVID-19 and pituitary hemorrhage.

Author Contributions

Conceptualization, M.A. and L.N.C.; methodology, M.A. and L.N.C.; validation, M.A., C.G.B., L.N.C., S.V., M.Ț., I.O.R., C.S.M., A.E.S. and S.F.; writing—original draft preparation, M.A.; writing—review and editing, L.N.C., S.F. and C.G.B.; visualization, M.A., C.G.B., L.N.C., S.V., M.Ț., I.O.R., C.S.M., A.E.S. and S.F.; supervision, L.N.C. and C.G.B.; project administration, L.N.C. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

This study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of Elias Hospital (04032025-1/4 March 2025).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study. Written informed consent has been obtained from the patient and his parents to publish this paper.

Data Availability Statement

Data supporting the published results are available from the corresponding author upon request.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Semple, P.L.; De Villiers, J.C.; Bowen, R.M.; Lopes, M.B.S.; Laws, E.R. Pituitary Apoplexy: Do Histological Features Influence the Clinical Presentation and Outcome? J. Neurosurg. 2006, 104, 931–937. [Google Scholar] [CrossRef] [PubMed]
  2. Bonicki, W.; Kasperlik-Załuska, A.; Koszewski, W.; Zgliczyński, W.; Wisławski, J. Pituitary Apoplexy: Endocrine, Surgical and Oncological Emergency. Incidence, Clinical Course and Treatment with Reference to 799 Cases of Pituitary Adenomas. Acta Neurochir. 1993, 120, 118–122. [Google Scholar] [CrossRef] [PubMed]
  3. Jankowski, P.P.; Crawford, J.R.; Khanna, P.; Malicki, D.M.; Ciacci, J.D.; Levy, M.L. Pituitary Tumor Apoplexy in Adolescents. World Neurosurg. 2015, 83, 644–651. [Google Scholar] [CrossRef]
  4. Biousse, V.; Newman, N.J.; Oyesiku, N.M. Precipitating Factors in Pituitary Apoplexy. J. Neurol. Neurosurg. Psychiatry 2001, 71, 542–545. [Google Scholar] [CrossRef] [PubMed]
  5. Randeva, H.S.; Schoebel, J.; Byrne, J.; Esiri, M.; Adams, C.B.T.; Wass, J.A.H. Classical Pituitary Apoplexy: Clinical Features, Management and Outcome. Clin. Endocrinol. 1999, 51, 181–188. [Google Scholar] [CrossRef]
  6. Mou, C.; Han, T.; Zhao, H.; Wang, S.; Qu, Y. Clinical Features and Immunohistochemical Changes of Pituitary Apoplexy. J. Clin. Neurosci. 2009, 16, 64–68. [Google Scholar] [CrossRef]
  7. Semple, P.L.; Jane, J.A.; Laws, E.R. Clinical Relevance of Precipitating Factors in Pituitary Apoplexy. Neurosurgery 2007, 61, 956–961. [Google Scholar] [CrossRef]
  8. Drury, P.L.; Belchetz, P.E.; Mcdonald, W.I.; Thomas, D.G.T.; Besser, G.M. Transient Amaurosis and Headache after Thyrotropin Releasing Hormone. Lancet 1982, 1, 218–219. [Google Scholar] [CrossRef]
  9. Arafah, B.M.; Taylor, H.C.; Salazar, R.; Saadi, H.; Selman, W.R. Apoplexy of a Pituitary Adenoma after Dynamic Testing with Gonadotropin-Releasing Hormone. Am. J. Med. 1989, 87, 103–105. [Google Scholar] [CrossRef]
  10. Vassallo, M.; Rana, Z.; Allen, S. Pituitary Apoplexy after Stimulation Tests. Postgrad. Med. J. 1994, 70, 444–445. [Google Scholar] [CrossRef]
  11. Rotman-Pikielny, P.; Patronas, N.; Papanicolaou, D.A. Pituitary Apoplexy Induced by Corticotrophin-Releasing Hormone in a Patient with Cushing’s Disease. Clin. Endocrinol. 2003, 58, 545–549. [Google Scholar] [CrossRef] [PubMed]
  12. Murad-Kejbou, S.; Eggenberger, E. Pituitary Apoplexy: Evaluation, Management, and Prognosis. Curr. Opin. Ophthalmol. 2009, 20, 456–461. [Google Scholar] [CrossRef] [PubMed]
  13. Ahmad, F.U.; Pandey, P.; Mahapatra, A.K. Post Operative “pituitary Apoplexy” in Giant Pituitary Adenomas: A Series of Cases. Neurol. India 2005, 53, 326–328. [Google Scholar] [CrossRef]
  14. Kinoshita, Y.; Tominaga, A.; Usui, S.; Arita, K.; Sakoguchi, T.; Sugiyama, K.; Kurisu, K. Pituitary Adenomas in Childhood and Adolescence with a Focus on Intratumoral Hemorrhage. Pituitary 2014, 17, 1–6. [Google Scholar] [CrossRef]
  15. Frara, S.; Allora, A.; Castellino, L.; di Filippo, L.; Loli, P.; Giustina, A. COVID-19 and the Pituitary. Pituitary 2021, 24, 465–481. [Google Scholar] [CrossRef]
  16. Solorio-Pineda, S.; Almendárez-Sánchez, C.A.; Tafur-Grandett, A.A.; Ramos-Martínez, G.A.; Huato-Reyes, R.; Ruiz-Flores, M.I.; Sosa-Najera, A. Pituitary Macroadenoma Apoplexy in a Severe Acute Respiratory Syndrome-Coronavirus-2-Positive Testing: Causal or Casual? Surg. Neurol. Int. 2020, 11, 304. [Google Scholar] [CrossRef]
  17. Bordes, S.J.; Phang-Lyn, S.; Najera, E.; Borghei-Razavi, H.; Adada, B. Pituitary Apoplexy Attributed to COVID-19 Infection in the Absence of an Underlying Macroadenoma or Other Identifiable Cause. Cureus 2021, 13, e13315. [Google Scholar] [CrossRef] [PubMed]
  18. Juul, A.; Skakkebæk, N.E. Why Do Normal Children Have Acromegalic Levels of IGF-I During Puberty? J. Clin. Endocrinol. Metab. 2019, 104, 2770–2776. [Google Scholar] [CrossRef]
  19. Yu, H.; Mistry, J.; Nicar, M.J.; Khosravi, M.J.; Diamandis, A.; Van Doorn, J.; Juul, A. Insulin-like Growth Factors (IGF-I, Free IGF-I, and IGF-II) and Insulin-like Growth Factor Binding Proteins (IGFBP-2, IGFBP-3, IGFBP-6, and ALS) in Blood Circulation. J. Clin. Lab. Anal. 1999, 13, 166. [Google Scholar] [CrossRef]
  20. Pascanu, I.; Pop, R.; Barbu, C.G.; Dumitrescu, C.P.; Gherlan, I.; Marginean, O.; Preda, C.; Procopiuc, C.; Vulpoi, C.; Hermanussen, M. Development of Synthetic Growth Charts for Romanian Population. Acta Endocrinol. 2016, 12, 309–318. [Google Scholar] [CrossRef]
  21. Pituitary Tumors and Neuroendocrine Disorders—Brigham and Women’s Hospital. Available online: https://www.brighamandwomens.org/neurosurgery/brain-tumors/pituitary-neuroendocrine-tumors (accessed on 16 April 2022).
  22. Briet, C.; Salenave, S.; Bonneville, J.-F.; Laws, E.R.; Chanson, P. Pituitary Apoplexy. Endocr. Rev. 2015, 36, 622–645. [Google Scholar] [CrossRef] [PubMed]
  23. Mindermann, T.; Wilson, C.B. Pediatric Pituitary Adenomas. Neurosurgery 1995, 36, 259–269. [Google Scholar] [CrossRef]
  24. Zijlker, H.; Schagen, S.; Wit, J.M.; Biermasz, N.; Van Furth, W.; Oostdijk, W. Pituitary Adenoma Apoplexy in an Adolescent: A Case Report and Review of the Literature. J. Clin. Res. Pediatr. Endocrinol. 2017, 9, 265. [Google Scholar] [CrossRef]
  25. Mauras, N.; Ross, J.; Mericq, V. Management of Growth Disorders in Puberty: GH, GnRHa, and Aromatase Inhibitors: A Clinical Review. Endocr. Rev. 2023, 44, 1–13. [Google Scholar] [CrossRef]
  26. Zhou, P.; Shah, B.; Prasad, K.; David, R. Letrozole Significantly Improves Growth Potential in a Pubertal Boy with Growth Hormone Deficiency. Pediatrics 2005, 115, e245. [Google Scholar] [CrossRef]
  27. Kumar, K.V.S.H.; Jayaraman, M.; Verma, A.; Modi, K.D. Letrozole as a Booster Therapy in Growth Hormone Deficiency. Indian. Pediatr. 2009, 46, 625–627. [Google Scholar] [PubMed]
  28. Miller, B.S.; Ross, J.; Ostrow, V. Height Outcomes in Children with Growth Hormone Deficiency and Idiopathic Short Stature Treated Concomitantly with Growth Hormone and Aromatase Inhibitor Therapy: Data from the ANSWER Program. Int. J. Pediatr. Endocrinol. 2020, 2020, 19. [Google Scholar] [CrossRef] [PubMed]
  29. Ranabir, S.; Baruah, M.P. Pituitary Apoplexy. Indian. J. Endocrinol. Metab. 2011, 15, S188. [Google Scholar] [CrossRef]
  30. Güneş, A.; Özbal Güneş, S. The Neuroimaging Features of Rathke’s Cleft Cysts in Children with Endocrine-Related Diseases. Diagn. Interv. Radiol. 2020, 26, 61–67. [Google Scholar] [CrossRef]
  31. Jung, H.N.; Kim, S.T.; Kong, D.S.; Suh, S.I.; Ryoo, I. Rathke Cleft Cysts with Apoplexy-Like Symptoms: Clinicoradiologic Comparisons with Pituitary Adenomas with Apoplexy. World Neurosurg. 2020, 142, e1–e9. [Google Scholar] [CrossRef]
  32. Iglesias, P. Pituitary Apoplexy: An Updated Review. J. Clin. Med. 2024, 13, 2508. [Google Scholar] [CrossRef] [PubMed]
  33. Kurokawa, R.; Kurokawa, M.; Baba, A.; Nakaya, M.; Kato, S.; Bapuraj, J.; Nakata, Y.; Ota, Y.; Srinivasan, A.; Abe, O.; et al. Neuroimaging of Hypophysitis: Etiologies and Imaging Mimics. Jpn. J. Radiol. 2023, 41, 911–927. [Google Scholar] [CrossRef] [PubMed]
  34. Boyke, A.E.; Michel, M.; Mamelak, A.N. Pituitary Apoplexy: A Re-Appraisal of Risk Factors and Best Management Strategies in the COVID-19 Era. Pituitary 2024, 27, 898–908. [Google Scholar] [CrossRef]
  35. Dubuisson, A.S.; Beckers, A.; Stevenaert, A. Classical Pituitary Tumour Apoplexy: Clinical Features, Management and Outcomes in a Series of 24 Patients. Clin. Neurol. Neurosurg. 2007, 109, 63–70. [Google Scholar] [CrossRef] [PubMed]
  36. Yamamoto, T.; Yano, S.; Kuroda, J.; Hasegawa, Y.; Hide, T.; Kuratsu, J. Pituitary Apoplexy Associated with Endocrine Stimulation Test: Endocrine Stimulation Test, Treatment, and Outcome. Case Rep. Endocrinol. 2012, 2012, 826901. [Google Scholar] [CrossRef]
  37. Piñar-Gutiérrez, A.; Remón-Ruiz, P.; Soto-Moreno, A. Case Report: Pituitary Apoplexy after COVID-19 Vaccination. Med. Clin. 2022, 158, 498–499. [Google Scholar] [CrossRef]
  38. Roncati, L.; Manenti, A. Pituitary Apoplexy Following Adenoviral Vector-Based COVID-19 Vaccination. Brain Hemorrhages 2022, 4, 27. [Google Scholar] [CrossRef]
  39. Ragni, A.; Biamonte, E.; Cavigiolo, B.; Mollero, E.L.M.; Bendotti, G.; Gabellieri, E.; Leporati, P.; Gallo, M. COVID19 Infection and Vaccination and the Risk of Pituitary Apoplexy: An Entangled Yarn. Endocrine 2024, 87, 459–467. [Google Scholar] [CrossRef]
  40. Verrienti, M.; Marino Picciola, V.; Ambrosio, M.R.; Zatelli, M.C. Pituitary and COVID-19 Vaccination: A Systematic Review. Pituitary 2024, 27, 970–985. [Google Scholar] [CrossRef]
  41. Martinez-Perez, R.; Kortz, M.W.; Carroll, B.W.; Duran, D.; Neill, J.S.; Luzardo, G.D.; Zachariah, M.A. Coronavirus Disease 2019 and Pituitary Apoplexy: A Single-Center Case Series and Review of the Literature. World Neurosurg. 2021, 152, e678. [Google Scholar] [CrossRef]
  42. Ragni, A.; Bendotti, G.; Biamonte, E.; Cavigiolo, B.; Gabellieri, E.; Leporati, P.; Mollero, E.L.M.; Gallo, M. SARS-CoV-2 Infection: A New Risk Factor for Pituitary Apoplexy? Endocr. Metab. Immune Disord. Drug Targets 2024, 24, 7. [Google Scholar] [CrossRef] [PubMed]
  43. LaRoy, M.; McGuire, M. Pituitary Apoplexy in the Setting of COVID-19 Infection. Am. J. Emerg. Med. 2021, 47, e1–e329. [Google Scholar] [CrossRef]
  44. Popov, D.; Hadzhiyanev, A. Pituitary Apoplexy Associated with COVID-19 Infection: Review and a Case Report. Biotechnol. Biotechnol. Equip. 2022, 36, 75–81. [Google Scholar] [CrossRef]
  45. Liew, S.Y.; Seese, R.; Shames, A.; Majumdar, K. Apoplexy in a Previously Undiagnosed Pituitary Macroadenoma in the Setting of Recent COVID-19 Infection. BMJ Case Rep. 2021, 14, e243607. [Google Scholar] [CrossRef] [PubMed]
  46. Silverman, M.N.; Pearce, B.D.; Biron, C.A.; Miller, A.H. Immune Modulation of the Hypothalamic-Pituitary-Adrenal (HPA) Axis during Viral Infection. Viral Immunol. 2005, 18, 41–78. [Google Scholar] [CrossRef]
  47. Hacohen, Y.; Abdel-Mannan, O.; Eyre, M.; Löbel, U.; Bamford, A.; Eltze, C.; Hameed, B.; Hemingway, C. Neurologic and Radiographic Findings Associated With COVID-19 Infection in Children. JAMA Neurol. 2020, 77, 1440–1445. [Google Scholar] [CrossRef]
  48. Özdağ Acarli, A.N.; Samanci, B.; Ekizoğlu, E.; Çakar, A.; Şirin, N.G.; Gündüz, T.; Parman, Y.; Baykan, B. Coronavirus Disease 2019 (COVID-19) From the Point of View of Neurologists: Observation of Neurological Findings and Symptoms During the Combat Against a Pandemic. Noro Psikiyatr. Ars. 2020, 57, 154–159. [Google Scholar] [CrossRef]
  49. Machhi, J.; Herskovitz, J.; Senan, A.M.; Dutta, D.; Nath, B.; Oleynikov, M.D.; Blomberg, W.R.; Meigs, D.D.; Hasan, M.; Patel, M.; et al. The Natural History, Pathobiology, and Clinical Manifestations of SARS-CoV-2 Infections. J. Neuroimmune Pharmacol. 2020, 15, 359–386. [Google Scholar] [CrossRef]
  50. Hussain, H.; Janaka, K.; Muthukuda, D.; Perera, S. Pituitary Apoplexy as a Complication of COVID-19 Infection. Cureus 2023, 15, e43524. [Google Scholar] [CrossRef]
  51. Aliberti, L.; Gagliardi, I.; Rizzo, R.; Bortolotti, D.; Schiuma, G.; Franceschetti, P.; Gafà, R.; Borgatti, L.; Cavallo, M.A.; Zatelli, M.C.; et al. Pituitary Apoplexy and COVID-19 Vaccination: A Case Report and Literature Review. Front. Endocrinol. 2022, 13, 1035482. [Google Scholar] [CrossRef]
  52. Garg, M.K.; Gopalakrishnan, M.; Yadav, P.; Misra, S. Endocrine Involvement in COVID-19: Mechanisms, Clinical Features, and Implications for Care. Indian. J. Endocrinol. Metab. 2020, 24, 381–386. [Google Scholar] [CrossRef] [PubMed]
  53. Ward, S.E.; Fogarty, H.; Karampini, E.; Lavin, M.; Schneppenheim, S.; Dittmer, R.; Morrin, H.; Glavey, S.; Ni Cheallaigh, C.; Bergin, C.; et al. ADAMTS13 Regulation of VWF Multimer Distribution in Severe COVID-19. J. Thromb. Haemost. 2021, 19, 1914–1921. [Google Scholar] [CrossRef] [PubMed]
  54. Shabbir, M.S.; Siddiqui, Q.A.; Shabbir, M.A. COVID-19 Induced Hypercoagulability and Its Impact Leading to Pituitary Apoplexy. J. Pak. Med. Assoc. 2025, 75, 694. [Google Scholar] [CrossRef] [PubMed]
  55. Chen, E.C.; Zon, R.L.; Battinelli, E.M.; Connors, J.M. Approach to the Patient with COVID-19-Associated Thrombosis: A Case-Based Review. Oncologist 2020, 25, e1500–e1508. [Google Scholar] [CrossRef]
  56. Chan, J.L.; Gregory, K.D.; Smithson, S.S.; Naqvi, M.; Mamelak, A.N. Pituitary Apoplexy Associated with Acute COVID-19 Infection and Pregnancy. Pituitary 2020, 23, 716–720. [Google Scholar] [CrossRef]
  57. Vilca-Alosilla, J.J.; Candia-Puma, M.A.; Coronel-Monje, K.; Goyzueta-Mamani, L.D.; Galdino, A.S.; Machado-de-Ávila, R.A.; Giunchetti, R.C.; Ferraz Coelho, E.A.; Chávez-Fumagalli, M.A. A Systematic Review and Meta-Analysis Comparing the Diagnostic Accuracy Tests of COVID-19. Diagnostics 2023, 13, 1549. [Google Scholar] [CrossRef]
  58. Barkhoudarian, G.; Kelly, D.F. Pituitary Apoplexy. Neurosurg. Clin. N. Am. 2019, 30, 457–463. [Google Scholar] [CrossRef]
  59. Turgut, M.; Özsunar, Y.; Başak, S.; Güney, E.; Kir, E.; Meteoǧlu, I. Pituitary Apoplexy: An Overview of 186 Cases Published during the Last Century. Acta Neurochir. 2010, 152, 749–761. [Google Scholar] [CrossRef]
  60. Gruber, A.; Clayton, J.; Kumar, S.; Robertson, I.; Howlett, T.; Mansell, P. Pituitary Apoplexy: Retrospective Review of 30 Patients—Is Surgical Intervention Always Necessary? Br. J. Neurosurg. 2006, 20, 379–385. [Google Scholar] [CrossRef]
  61. Tu, M.; Lu, Q.; Zhu, P.; Zheng, W. Surgical versus Non-Surgical Treatment for Pituitary Apoplexy: A Systematic Review and Meta-Analysis. J. Neurol. Sci. 2016, 370, 258–262. [Google Scholar] [CrossRef]
  62. Leyer, C.; Castinetti, F.; Morange, I.; Gueydan, M.; Oliver, C.; Conte-Devolx, B.; Dufour, H.; Brue, T. A Conservative Management Is Preferable in Milder Forms of Pituitary Tumor Apoplexy. J. Endocrinol. Investig. 2011, 34, 502–509. [Google Scholar] [CrossRef]
  63. Giritharan, S.; Gnanalingham, K.; Kearney, T. Pituitary Apoplexy—Bespoke Patient Management Allows Good Clinical Outcome. Clin. Endocrinol. 2016, 85, 415–422. [Google Scholar] [CrossRef] [PubMed]
  64. Grzywotz, A.; Kleist, B.; Möller, L.C.; Hans, V.H.; Göricke, S.; Sure, U.; Müller, O.; Kreitschmann-Andermahr, I. Pituitary Apoplexy—A Single Center Retrospective Study from the Neurosurgical Perspective and Review of the Literature. Clin. Neurol. Neurosurg. 2017, 163, 39–45. [Google Scholar] [CrossRef]
  65. Finsterer, J. Pituitary Apoplexy Is Not Uncommon in Pediatric Patients and Can Be a Manifestation of Neuro-COVID. Ann. Pediatr. Endocrinol. Metab. 2023, 28, 73. [Google Scholar] [CrossRef] [PubMed]
  66. Ohata, H.; Shinde, B.; Nakamura, H.; Teranishi, Y.; Morisako, H.; Ohata, K.; Goto, T. Pituitary Apoplexy in a Puberal Child: A Case Report and Review of the Literature. Interdiscip. Neurosurg. 2021, 25, 101160. [Google Scholar] [CrossRef]
  67. Guan, H.; Zhang, Y.; Wang, X. Rathke’s Cleft Cyst Apoplexy in a Boy Treated by Endoscopic Endonasal Surgery: Case Report and Literature Review. Neurochirurgie 2024, 70, 101540. [Google Scholar] [CrossRef]
  68. Al-Juboori, A.A.; Badran, S.A.; Shahadha, A.A.; Alsamok, A.S.; Ismail, M. Transnasal Transsphenoidal Approach for a Nine-Year-Old Child With Pituitary Apoplexy: A Case Report. Cureus 2024, 16, e64525. [Google Scholar] [CrossRef]
  69. Agrawal, P.; Newbold, S.; Al Busaidi, A.; Kapoor, R.R.; Thomas, N.; Aylwin, S.J.B.; Buchanan, C.R.; Arya, V.B. Pituitary Apoplexy in an Adolescent Male with Macroprolactinoma Presenting as Middle Cerebral Artery Territory Infarction. Ann. Pediatr. Endocrinol. Metab. 2022, 27, 320–324. [Google Scholar] [CrossRef]
  70. Orr, T.; Lesha, E.; Dugan, J.E.; Cecia, A.; Kramer, A.H.; Blum, D.; Zhang, J.; Klimo, P. Langerhans Cell Histiocytosis of the Sella in a Pediatric Patient: Case Report with Review of the Literature. Child’s Nerv. Syst. 2024, 40, 2947–2952. [Google Scholar] [CrossRef]
Diagnostics 15 01453 g001
Figure 1. November 2021 MRI scan: (a) T1 TSE (turbo spin echo) sagittal; (b) T1 TSE FS (fat-suppressed) coronal; (c) FLAIR sagittal; (d) T2 TSE coronal.
Figure 1. November 2021 MRI scan: (a) T1 TSE (turbo spin echo) sagittal; (b) T1 TSE FS (fat-suppressed) coronal; (c) FLAIR sagittal; (d) T2 TSE coronal.
Diagnostics 15 01453 g001
Diagnostics 15 01453 g002
Figure 2. Growth history during follow-up with a measurement error range of 0.5 cm [20].
Figure 2. Growth history during follow-up with a measurement error range of 0.5 cm [20].
Diagnostics 15 01453 g002
Diagnostics 15 01453 g003
Figure 3. March 2025 MRI scan: (a) FLAIR coronal; (b) T2 TSE coronal; (c) T1 TSE coronal; (d) T1 TSE FS coronal +Gd; (e) T1 TSE sagittal; (f) T1 TSE sagittal +Gd.
Figure 3. March 2025 MRI scan: (a) FLAIR coronal; (b) T2 TSE coronal; (c) T1 TSE coronal; (d) T1 TSE FS coronal +Gd; (e) T1 TSE sagittal; (f) T1 TSE sagittal +Gd.
Diagnostics 15 01453 g003
Table 1. Treatment-related characteristics during follow-up.
Table 1. Treatment-related characteristics during follow-up.
IGF1 (ng/mL)/
(Z-Score for Tanner)		Height
(cm)/(SD)		Weight (kg)rGH Dose
(mg/kg/day)		Letrozole
(mg/day)
November 2021116.1/−2.18141/−2.6839--
January 2022141.7/−3.25144.1/−2.4240.8Start 0.03Start 2.5
February 2022257.4/−1.8 0.03, ↑ to 0.042.5
March 2022504.9/+0.98145.7/−2.3842.20.042.5
June 2022387.9/+0.16149.5/−2.1044.50.04, ↑ to 0.0452.5
December 2022337.6/−0.45155.3/−1.82510.0452.5
May 2023298.4/−0.96160.6/−1.46570.045, ↑ to 0.052.5
November 2023633.3/+3164.4/−1.26610.05, ↓ to 0.0452.5
May 2024482.9/+1.44169.2/−0.8369.30.0452.5, STOP
November 2024525.1/+2.26172.3/−0.5169.80.045, STOP
Bone age 16 years old
↑—dose increase; ↓—dose decrease.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Barbu, C.G.; Cima, L.N.; Andrei, M.; Vasilache, S.; Țarnă, M.; Rizea, I.O.; Martin, C.S.; Sîrbu, A.E.; Fica, S. Pituitary Apoplexy in a Child with Short Stature and Possible Recent SARS-CoV-2 Infection. Diagnostics 2025, 15, 1453. https://doi.org/10.3390/diagnostics15121453

AMA Style

Barbu CG, Cima LN, Andrei M, Vasilache S, Țarnă M, Rizea IO, Martin CS, Sîrbu AE, Fica S. Pituitary Apoplexy in a Child with Short Stature and Possible Recent SARS-CoV-2 Infection. Diagnostics. 2025; 15(12):1453. https://doi.org/10.3390/diagnostics15121453

Chicago/Turabian Style

Barbu, Carmen Gabriela, Luminita Nicoleta Cima, Marian Andrei, Simona Vasilache, Mihaela Țarnă, Ileana Olguta Rizea, Carmen Sorina Martin, Anca Elena Sîrbu, and Simona Fica. 2025. "Pituitary Apoplexy in a Child with Short Stature and Possible Recent SARS-CoV-2 Infection" Diagnostics 15, no. 12: 1453. https://doi.org/10.3390/diagnostics15121453

APA Style

Barbu, C. G., Cima, L. N., Andrei, M., Vasilache, S., Țarnă, M., Rizea, I. O., Martin, C. S., Sîrbu, A. E., & Fica, S. (2025). Pituitary Apoplexy in a Child with Short Stature and Possible Recent SARS-CoV-2 Infection. Diagnostics, 15(12), 1453. https://doi.org/10.3390/diagnostics15121453

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop